GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dova Pharmaceuticals Inc (NAS:DOVA) » Definitions » Gross Margin %

Dova Pharmaceuticals (Dova Pharmaceuticals) Gross Margin % : 80.64% (As of Sep. 2019)


View and export this data going back to 2017. Start your Free Trial

What is Dova Pharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Dova Pharmaceuticals's Gross Profit for the three months ended in Sep. 2019 was $2.72 Mil. Dova Pharmaceuticals's Revenue for the three months ended in Sep. 2019 was $3.37 Mil. Therefore, Dova Pharmaceuticals's Gross Margin % for the quarter that ended in Sep. 2019 was 80.64%.


The historical rank and industry rank for Dova Pharmaceuticals's Gross Margin % or its related term are showing as below:


DOVA's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 59.905
* Ranked among companies with meaningful Gross Margin % only.

Dova Pharmaceuticals had a gross margin of 80.64% for the quarter that ended in Sep. 2019 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Dova Pharmaceuticals was 0.00% per year.


Dova Pharmaceuticals Gross Margin % Historical Data

The historical data trend for Dova Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dova Pharmaceuticals Gross Margin % Chart

Dova Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18
Gross Margin %
- - 88.60

Dova Pharmaceuticals Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 87.37 89.76 87.13 87.37 80.64

Competitive Comparison of Dova Pharmaceuticals's Gross Margin %

For the Biotechnology subindustry, Dova Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dova Pharmaceuticals's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dova Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Dova Pharmaceuticals's Gross Margin % falls into.



Dova Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Dova Pharmaceuticals's Gross Margin for the fiscal year that ended in Dec. 2018 is calculated as

Gross Margin % (A: Dec. 2018 )=Gross Profit (A: Dec. 2018 ) / Revenue (A: Dec. 2018 )
=9.2 / 10.355
=(Revenue - Cost of Goods Sold) / Revenue
=(10.355 - 1.18) / 10.355
=88.60 %

Dova Pharmaceuticals's Gross Margin for the quarter that ended in Sep. 2019 is calculated as


Gross Margin % (Q: Sep. 2019 )=Gross Profit (Q: Sep. 2019 ) / Revenue (Q: Sep. 2019 )
=2.7 / 3.373
=(Revenue - Cost of Goods Sold) / Revenue
=(3.373 - 0.653) / 3.373
=80.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Dova Pharmaceuticals  (NAS:DOVA) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Dova Pharmaceuticals had a gross margin of 80.64% for the quarter that ended in Sep. 2019 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Dova Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of Dova Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Dova Pharmaceuticals (Dova Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
240 Leigh Farm Road, Suite 245, Durham, NC, USA, 27707
Dova Pharmaceuticals Inc is a United States based clinical-stage pharmaceutical company engaged in developing treatments for patients suffering from orphan diseases. It is focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. The company's drug candidate, avatrombopag, is an orally administered thrombopoietin receptor agonist, or TPO-RA, that it is developing for the treatment of thrombocytopenia. The company's drug candidate, avatrombopag, is designed to mimic the effects of thrombopoietin, in vitro and in vivo. Thrombopoietin is a hormone produced in the liver and kidney that binds to its receptor.
Executives
Nancy Wysenski director 2200 SUNBURST STREET, CHATSWORTH CA 90401
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Allen Lee F Md Phd officer: Chief Medical Officer C/O AMAG PHARMACEUTICALS, INC., 125 CAMBRIDGEPARK DRIVE, 6TH FLOOR, CAMBRIDGE MA 02140
Roger Jeffs director
Alfred J Novak director 325 NE 6TH ST, BOCA RATON FL 33432
David Zaccardelli director, officer: President & CEO 300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069
Paul B Manning director, 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Stalfort John A Iii director C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Jason Hoitt officer: Chief Commercial Officer C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707
Alex Sapir director, officer: President & CEO C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707

Dova Pharmaceuticals (Dova Pharmaceuticals) Headlines

From GuruFocus